Scarica l'app Stockscreener
4.9312
1.18%
-0.0588
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$4.99
Aprire:
$4.97
Volume 24 ore:
1,290
Relative Volume:
0.03
Capitalizzazione di mercato:
$4.63M
Reddito:
$61,000
Utile/perdita netta:
$-5.46M
Rapporto P/E:
-0.754
EPS:
-6.54
Flusso di cassa netto:
$-6.76M
1 W Prestazione:
-4.80%
1M Prestazione:
+21.16%
6M Prestazione:
+33.64%
1 anno Prestazione:
-19.56%
Intervallo 1D:
$4.97
$5.09
Intervallo di 1 settimana:
$4.31
$5.335
Portata 52W:
$3.03
$6.99
Titan Pharmaceuticals Inc De Stock (TTNP) Company Profile
Nome
Titan Pharmaceuticals Inc De
Settore
Industria
Telefono
(650) 244-4990
Indirizzo
400 OYSTER POINT BLVD, SAN FRANCISCO
Confronta TTNP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TTNP
Titan Pharmaceuticals Inc De
|
5.06 | 6.89M | 61,000 | -5.46M | -6.76M | -6.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.31 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.07 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
450.04 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
691.80 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
315.31 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Titan Pharmaceuticals Inc De Stock (TTNP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2019-06-26 | Iniziato | Maxim Group | Buy |
| 2017-11-10 | Downgrade | ROTH Capital | Buy → Neutral |
Titan Pharmaceuticals Inc De Borsa (TTNP) Ultime notizie
Will a bounce in CEMEX S.A.B. de C.V. Depositary Receipt offer an exitJuly 2025 Analyst Calls & High Accuracy Swing Entry Alerts - Newser
Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) Short Interest Up 304.7% in July - Defense World
Elite Pharmaceuticals Revenue More Than Doubles as New ADHD Drug Launch Drives Record Growth - Stock Titan
How Titan Pharmaceuticals Inc. stock performs during market volatilityMarket Growth Summary & Expert Curated Trade Ideas - Newser
Sonoma's First Major Consumer Product Hits Walmart Shelves: New Tech-Based Diaper Rash Treatment - Stock Titan
Ketamir-2 outperforms ketamine, plans Phase 2a FDA submission in Q4 2025 - Stock Titan
CVKD Files 8-K; Exhibit 99.1 Contains Q2 2025 Financials - Stock Titan
Will earnings trigger a reversal in Titan Pharmaceuticals Inc.Daily Swing Candidate Analysis with Chart Patterns - Newser
Best Pharmaceutical Stocks to Buy in 2025 - The Motley Fool
Elite Pharmaceuticals Earnings Call: Key Corporate Updates and Q1 2026 Results Coming August 15 - Stock Titan
NRx Secures Florida Approval to Acquire Veterans Mental Health Provider Dura Medical - Stock Titan
Kiora's Q2 Earnings Reveal Dual Phase 2 Trials Progress and $110M Asia Partnership Opportunity - Stock Titan
PLBY regains Nasdaq compliance with new independent director appointment | PCSA SEC FilingForm 8-K - Stock Titan
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates - GlobeNewswire
RIGL files S-8 to register 825,000 shares for employee equity plans | RIGL SEC FilingForm S-8 - Stock Titan
TITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc.TTNP - FinancialContent
Cumberland Pharmaceuticals Hits 23% Revenue Growth as DMD Drug Shows Major Heart Benefits - Stock Titan
Nuvectis Reports Clinical Trial Success: NXP900 Cancer Drug Advances as Cash Position Strengthens to $39M - Stock Titan
Biotech Terns Pharmaceuticals Appoints Chief People Officer, Awards Massive 500,000 Share Option Package - Stock Titan
Ex-Takeda Rare Disease Chief Joins Catalyst Pharmaceuticals Board to Drive Strategic Growth - Stock Titan
Xenon Pharmaceuticals Expands Team: Grants $739K in Stock Options to 6 New Hires - Stock Titan
SHEN files 8-K, releases Q2 2025 earnings press release | ADIL SEC FilingForm 424B5 - Stock Titan
Acurx Pharmaceuticals Plans Major 1:20 Reverse SplitKey Details for Nasdaq Compliance - Stock Titan
Lexicon Pharmaceuticals Meets $1 Minimum Share Price, Secures Critical Nasdaq Listing Status - Stock Titan
Cumberland Pharmaceuticals Sets Q2 Earnings Date: FDA-Approved Drug Portfolio Update Coming August 5 - Stock Titan
NRx Pharmaceuticals Teams with Yale Expert to Reveal Latest CNS Treatment Innovations at BTIG Conference - Stock Titan
MIRA's Novel Pain Drug Shows 112% Better Relief Than Current Treatments, FDA Gives Green Light - Stock Titan
INM files 8-K on upcoming INM-901 Alzheimer’s data at AAIC 2025 | INM SEC FilingForm 8-K - Stock Titan
Supernus-Sage $12B Merger Gets Key Regulatory Green Light as Tender Offer Deadline Nears - Stock Titan
What are the latest earnings results for Titan Pharmaceuticals Inc.Achieve explosive financial results today - Jammu Links News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CARM, ENZB, HSON, TTNP on Behalf of Shareholders - GlobeNewswire Inc.
Phio Pharmaceuticals Advances Cancer Drug Production with Strategic US Manufacturing Partnership - Stock Titan
Apellis Pharmaceuticals Q2 Earnings: Complement Medicine Pioneer Reports Latest Financial Performance - Stock Titan
Lexicon Pharmaceuticals Schedules Pre-Market Q2 Earnings Release, 8:30 AM ET Conference Call - Stock Titan
CNS Pharmaceuticals CEO Shares Brain Cancer Treatment Vision at Investor Conference | CNSP Stock News - Stock Titan
Amneal (AMRX) targets $2.55B debt refinancing via loans & notes | AMRX SEC FilingForm 8-K - Stock Titan
MEI Pharma Announces $100,000,000 Private Placement to Initiate Litecoin Treasury Strategy, Becoming First and Only Publicly Traded LTC Holder on a National Exchange - Business Wire
What analysts say about Titan Pharmaceuticals Inc. stockFree Smart Trading Workshop - jammulinksnews.com
HOOKIPA Pharma Exits Nasdaq Market as Gilead Sciences Acquires Key Drug Programs - Stock Titan
60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering - Stock Titan
Rani Therapeutics Secures $3M Financing Deal: Biotech Firm Prices Shares at $0.40 in Strategic Offering - Stock Titan
Major FDA Development: Pierre Fabre Assumes Control of Atara's EBV Cell Therapy Program After BLA Resubmission - Stock Titan
INKT sets up $50M ATM with B. Riley, adds financing flexibility | INKT SEC FilingForm 8-K - Stock Titan
ESSA Pharma Shareholders to Receive $1.91 Cash Plus CVR in XenoTherapeutics Acquisition Deal - Stock Titan
RYTM raises $188.7M via 2.37M-share offering at $85 | RYTM SEC FilingForm 8-K - Stock Titan
MIST gets FDA review nod; PDUFA set for Dec 13 2025 – covenant aligned | MIST SEC FilingForm 8-K - Stock Titan
FDA Sets New December 2025 Decision Date for Milestone's PSVT Nasal Spray, Secures $75M Funding - Stock Titan
Local Bounti (LOCL) insider files Form 144 to sell 3,500 shares - Stock Titan
Rhythm Pharmaceuticals Raises Massive $175M in Upsized Offering for Rare Disease Drug Development - Stock Titan
GILT lands >$22M Tier-One satellite orders, boosts multi-orbit momentum | EVOK SEC FilingForm 8-K - Stock Titan
Citius Pharma Dodges Delisting: Stock Maintains $1+ Price for 10 Straight Days, Secures Nasdaq Future - Stock Titan
Titan Pharmaceuticals Inc De Azioni (TTNP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.39%
0.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):